Cue Biopharma, Inc. SEC filings CUE
Cue Biopharma, Inc. has 552 filings in SEC EDGAR's recent list, going back to Jun 19, 2015. Its latest annual report, Form ARS, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | May 21, 2026 | Jun 1, 2026 |
| PRE 14A | Preliminary proxy statement | May 11, 2026 | Jun 1, 2026 |
| DEFA14A | Additional proxy material | Mar 27, 2026 | — |
| DEF 14A | Proxy statement | Mar 16, 2026 | Mar 16, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 6, 2026 | Mar 6, 2026 |
| DEFA14A | Additional proxy material | May 27, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 3, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| PRE 14A | Preliminary proxy statement | Apr 14, 2025 | Apr 14, 2025 |
| DEF 14A | Proxy statement | Sep 10, 2024 | Oct 8, 2024 |
| PRE 14A | Preliminary proxy statement | Aug 28, 2024 | Oct 8, 2024 |
| DEFA14A | Additional proxy material | May 24, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 5, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 7, 2023 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 9, 2022 |
| DEFA14A | Additional proxy material | Apr 26, 2021 | — |
| DEF 14A | Proxy statement | Apr 26, 2021 | Jun 9, 2021 |
| DEFA14A | Additional proxy material | May 29, 2020 | — |
| DEF 14A | Proxy statement | May 29, 2020 | Jul 9, 2020 |
| PRE 14A | Preliminary proxy statement | May 15, 2020 | Jul 9, 2020 |
| DEFA14A | Additional proxy material | Jun 18, 2019 | — |
| DEF 14A | Proxy statement | Jun 18, 2019 | Aug 6, 2019 |
| PRE 14A | Preliminary proxy statement | May 30, 2019 | Aug 6, 2019 |
| DEFA14A | Additional proxy material | May 29, 2018 | — |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 12, 2018 |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CUE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Somerville, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1645460
- Former names
- Imagen Biopharma, Inc. (until Jun 19, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.